Oba, Mari S., Miyaji, Tempei, Bando, Hiroko, Ueda, Aya, Terada, Kaori, Doi, Mihoko, Nagai, Shigenori, Hattori, Masaya, Watanabe, Kenichi, Tamura, Nobuko, et al. Examining the association between patient-reported outcomes and physical activity metrics in patients with HR1/ HER2 advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone. QUALITY OF LIFE RESEARCH. 2024. 33. 1. S40-S41
Sasaki, Keita, Mizusawa, Junki, Bando, Hiroko, Nakamura, Kenichi, Kataoka, Tomoko, Katayama, Hiroshi, Fukuda, Haruhiko, Hara, Hisato. Consideration of factors of low accrual and methods for setting appropriate accrual periods: Japan Clinical Oncology Group study. TRIALS. 2024. 25. 1
Cardiovascular and Non cardiovascular Risks among Female Breast Cancer Survivors in Japan A Matched Cohort Study
(SAN ANTONIO BREAST CANCER SYMPOSIUM 2024)
Subtype by PAM50 changes after Neoadjuvant Endocrine therapy, from A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy plus Palbociclib versus Hormonal Therapy plus Placebo in ER+HER2- Operable Breast Cancer
(SAN ANTONIO BREAST CANCER SYMPOSIUM 2024)
Potential risk factors for health related quality of life HRQoL in palbociclib PAL plus endocrine therapy ET and ET alone patients with HR HER2 advanced breast cancer ABC exploratory analysis from 6 month longitudinal study JBCRG 26
(SAN ANTONIO BREAST CANCER SYMPOSIUM 2024)